- Home
- CRMD
CRMD
CorMedix Inc.
as 10-13-2025 3:55pm EST
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BERKELEY HEIGHTS |
| Market Cap: | 865.2M | IPO Year: | 2010 |
| Target Price: | $17.57 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $17.43 | Next Earning Date: | 10-29-2025 |
| Revenue: | $121,484,498 | Revenue Growth: | 14970.29% |
| Revenue Growth (this year): | 480.51% | Revenue Growth (next year): | 59.81% |
Stock Insider Trading Activity of CorMedix Inc. (CRMD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DUNTON ALAN W | CRMD | Director | Sep 12 '25 | Sell | $13.13 | 10,000 | $131,300.00 | 40,250 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 11 '25 | Sell | $13.08 | 41,121 | $537,862.68 | 176,990 | |
| Zelnick Kaufman Beth | CRMD | Chief Legal Officer | Sep 9 '25 | Sell | $13.12 | 50,000 | $670,264.00 | 180,818 | |
| Masson-Hurlburt Elizabeth | CRMD | Chief Operating Officer | Sep 9 '25 | Sell | $13.51 | 12,876 | $173,954.76 | 176,990 |
Latest CorMedix Inc. News
CRMD Breaking Stock News: Dive into CRMD Ticker-Specific Updates for Smart Investing
Zacks
21 days ago
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
Zacks
22 days ago
SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU
Zacks
22 days ago
FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing
Zacks
a month ago
RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal
Zacks
a month ago
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Zacks
a month ago
RARE Reports Positive Long-Term Data From Metabolic Disorder Study
Zacks
a month ago
CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Barchart
4 months ago
S&P 500 and Nasdaq Climb to Record Highs on China Trade Optimism
Compare CRMD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRMD CorMedix Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.